<?xml version="1.0" encoding="UTF-8"?>
<p>This compound has been related to multiple biological effects, such as immunomodulation induced by NF-
 <italic>κ</italic>B activation and downregulation of Mcl-1 expression to suppress ovarian cancer growth [
 <xref rid="B36-biomolecules-11-00011" ref-type="bibr">36</xref>], anti-apoptosis effects caused by radiation damage and enhanced antioxidant enzymes in Chinese hamster lung fibroblasts (V79-4), a Hps90 ATPase inhibitor [
 <xref rid="B37-biomolecules-11-00011" ref-type="bibr">37</xref>] and anti-
 <italic>Plasmodium falciparum</italic> in vitro (IC
 <sub>50</sub>: 11.74 µM) [
 <xref rid="B36-biomolecules-11-00011" ref-type="bibr">36</xref>]. Antiviral in vitro effects of geraniin have also been reported against enterovirus 71 (EV71) (IC
 <sub>50</sub>: 10 μg/mL) [
 <xref rid="B38-biomolecules-11-00011" ref-type="bibr">38</xref>], herpes simplex virus type 2 (HSV-2) (IC
 <sub>50</sub>: 18.4 ± 2.0 µM) [
 <xref rid="B39-biomolecules-11-00011" ref-type="bibr">39</xref>], human immunodeficiency virus (HIV) (IC
 <sub>50</sub>: 0.48–6.28 μg/mL by multiple mechanisms of action) [
 <xref rid="B40-biomolecules-11-00011" ref-type="bibr">40</xref>], hepatitis B (HBV) (200 μg/mL, inhibition of HBsAg and HBeAg secretion, 85.8 ± 7.3% and 63.7 ± 6.8, respectively) [
 <xref rid="B41-biomolecules-11-00011" ref-type="bibr">41</xref>], Epstein–Barr virus (EBV) (IC
 <sub>50</sub>: 15.7 µM, inhibition of DNA polymerase) [
 <xref rid="B42-biomolecules-11-00011" ref-type="bibr">42</xref>], and hepatitis C virus (HCV) (IC
 <sub>50</sub>: 8.91 µM, inhibition of NS3-4A protease) [
 <xref rid="B43-biomolecules-11-00011" ref-type="bibr">43</xref>].
</p>
